- $125.62m
- -$28.41m
Brief: Kinnate Biopharma Inc. Announces Acquisition Of Ownership Stake From Series A Investors Of The China Joint Venture, Kinnjiu Biopharma Inc., And Initiation Of Phase 1 Clinical Trial For Exarafenib (Kin-2787) In People's Republic Of China
U.S. STOCKS ON THE MOVE-Bank of America, Silvergate Capital, Energy firms
Kinnate rises on FDA's fast track tag for bile duct cancer treatment
Brief: Kinnate Biopharma Receives Fast Track Designation From FDA For Cancer Therapy
Kinnate Biopharma Inc reports results for the quarter ended in September - Earnings Summary
Brief: Kinnate Biopharma Inc. Announces Third Quarter 2022 Financial Results And Recent Corporate Updates
Kinnate Biopharma Inc expected to post a loss of 61 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Apple, BlackRock, U.S. homebuilders, Pfizer
Kinnate hits record low on delaying early-stage data for cancer therapy
Brief: Kinnate Biopharma Announces Recent Corporate Updates
Brief: Kinnate Biopharma Receives Fast Track Designation From FDA For Kin-2787
Kinnate Biopharma Inc reports results for the quarter ended in June - Earnings Summary
Brief: Kinnate Biopharma Inc - QTRLY Loss Per Share $0.62
Kinnate Biopharma Inc reports results for the quarter ended in March - Earnings Summary
Kinnate Biopharma Inc expected to post a loss of 64 cents a share - Earnings Preview
Brief: Kinnate Doses First Patient In Phase 1 Clinical Trial Of FGFR Inhibitor Product Candidate
Kinnate Biopharma Inc reports results for the quarter ended in December - Earnings Summary
Brief: Kinnate Biopharma Reports Full Year 2021 Financial Results And Provides Operational Updates
Kinnate Biopharma Inc expected to post a loss of 59 cents a share - Earnings Preview